Financials in USD. Standardized financial statements.
A compact view of how Universal Ibogaine Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue? | $1.07M | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $1.07M | $0 | $0 | $0 | $0 |
| Gross Margin? | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $5.82M | $3.86M | $59,244 | $68,850 | $176,229 |
| Operating Income? | $497,151 | -$3.83M | $383 | -$33,861 | $63,952 |
| EBITDA? | -$4.61M | -$3.76M | $638 | -$33,861 | $63,952 |
| Income Before Tax | -$10.50M | -$3.87M | -$118,309 | -$98,109 | -$408,289 |
| Income Tax Expense | -$59,803 | $15,005 | $59,065 | $0 | $0 |
| Net Income? | -$10.50M | -$3.87M | -$118,309 | -$98,109 | -$408,289 |
| EPS? | $-0.06 | $-0.03 | $-0.01 | $-0.01 | $-0.04 |
| Diluted EPS? | $-0.06 | $-0.03 | $-0.01 | $-0.01 | $-0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality